Efficacy and Safety of Bevacizumab Biosimilar FKB238 Versus Originator Bevacizumab: Results from AVANA, a Phase III Trial in Patients with Non-Squamous Non-Small-Cell Lung Cancer (non-sq-NSCLC)

Syrigos, K; Abert, I; Andric, Z; Bondarenko, IN; Dvorkin, M; Galic, K; Galiulin, R; Kuchava, V; Sriuranpong, V; Trukhin, D; Zhavrid, E; Fu, DY; Kassalow, LM; Jones, S; Bashir, Z

Bashir, Z (corresponding author), Transcrip Partners, Reading, Berks, England.; Bashir, Z (corresponding author), Centus Biotherapeut, 1 Francis Crick Ave,Cambridge Biomed Campus, Cambridge CB2 0AA, England.

BIODRUGS, 2021; 35 (4): 417

Abstract

Background Bevacizumab is an antiangiogenic recombinant humanized monoclonal antibody that inhibits tumor growth. FKB238, a bevacizumab biosimilar, ha......

Full Text Link


Links

期刊讨论 | 中国SCI论文 | 期刊主页 | 投稿经验 | 杂志官网 | 投稿链接 | 作者需知 | PMC链接 | Pubmed全文检索